1 uscular junction blockers (sensitive only to decamethonium).

2 bisquaternary compounds such as BW284C51 and decamethonium.

3 haracterized with respect to edrophonium and decamethonium.

4                  Hexamethonium (500 microM), decamethonium (500 microM), mecamylamine (50 microM), pe

5 lycaconitine, d-tubocurarine, hexamethonium, decamethonium, and mecamylamine either failed to up-regu

6 ive antagonism by dihydro-beta-erythroidine, decamethonium, and methyllycaconitine; noncompetitive an

7                                 Edrophonium, decamethonium, and propidium, three quaternary AChE liga

8 ke potent OCT1 blockers (1,10-diaminodecane, decamethonium, bistriethylaminodecane, and 1,10-bisquinu

9 resence or absence of the cationic additive, decamethonium bromide were ineffective for resolving IGF

10 inhibitor complexes (EDR/AChE, THA/AChE, and decamethonium (DCM)/AChE) provided information regarding

11 onstants increased 3.3-12.0-fold; 200 microM decamethonium produced a 1.6-3.0-fold enhancement of rea

12      The diquaternary amines dimethonium and decamethonium were relatively ineffective inhibitors.

13  to accelerate by quaternary ligands such as decamethonium, which is devoid of nucleophilicity.